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Veillonella parvula is an anaerobic gram-negative coccus that is part of the normal flora of the animal and human
mouth and gastrointestinal and genitourinary tracts. Oral V. parvula is involved in the development of early
periodontal disease as well as different types of serious infections. Present data on molecular mechanisms respon-
sible for innate immune response against Veillonella are very scanty. The aim of this study was to investigate the
Toll-like receptor (TLR) pathways responsible for V. parvula lipopolysaccharide (LPS) and to identify the intracel-
lular pathways induced by this recognition. V. parvula LPS stimulated tumor necrosis factor alpha (TNF-) and
interleukin-6 (IL-6) release in human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner.
Pretreatment of cells with a TLR4 antagonist significantly reduced TNF- and IL-6 production in PBMC stimulated
with either Veillonella orEscherichia coli LPS. However, V. parvula LPS was 10- to 100-fold less active thanE. coli LPS
for cytokine induction. TNF-, IL-1, IL-6, and IL-10 were released in wild-type and TLR2/, but not TLR4/,
mouse macrophage cultures. V. parvula LPS was able to activate the human PBMC p38 mitogen-activated protein
kinase (MAPK). A specific p38 MAPK inhibitor strongly inhibited V. parvula LPS-induced TNF-, IL-1, IL-6, and
IL-10. In conclusion, V. parvula LPS is able to induce cytokine production in both human and murine in vitro
models, although it is less effective than Enterobacteriaceae LPS. V. parvula LPS-stimulated cytokine induction, as
well as p38 MAPK activation, are TLR4-dependent features.
Veillonella organisms are small, nonfermentative, strictly an-
aerobic, gram-negative cocci which form part of the normal
flora of the oral, genitourinary, respiratory, and intestinal
tracts of humans and animals (10). The genus Veillonella was
first isolated by Veillon and Zuber in 1898 and currently con-
sists of eight species (28).
Veillonella species have been reported as causes of serious
infections, including meningitis (6), osteomyelitis and discitis
(7, 28), prosthetic joint infection (26), and acute and chronic
pleuropulmonary infection (33).
Risk factors for Veillonella infection include periodontal dis-
ease, immunodeficiency, intravenous drug use, and premature
birth (28). V. parvula is an important pathogen implicated in
periodontitis and other dental infections (3, 18), and it is one
of the most common anaerobic pathogens in chronic maxillary
sinusitis and deep neck infections (9, 37). V. parvula has also
been reported as a pathogen for osteomyelitis (34) and ab-
scessed orchiepididymitis with sepsis (4). Endovascular infec-
tions reportedly may range from bacteremia to severe endo-
carditis and fatal cases of sepsis (8, 14, 25).
Lipopolysaccharides (LPS) are major pathogenic factors of
gram-negative bacteria. LPS from aerobic and facultative bac-
teria have been extensively studied (5). On the contrary, very
little is known regarding the biological activity of LPS from
anaerobic microorganisms such as Veillonella (10, 24, 29, 32).
In addition, little is known about cellular and molecular mech-
anisms responsible for innate immune response against V. par-
vula, as well as for inflammatory reactions leading to severe
periodontitis or sinusitis. Toll-like receptors (TLRs) recognize
microbial compounds (36) and trigger the inflammatory and
immune responses against pathogens. Immunohistochemical
localization of TLR2 and TLR4 in gingival tissue of periodon-
titis patients has been reported (30). In mammals, engagement
of TLRs by LPS results in the recruitment of cytoplasmic
signaling molecules (12, 36), which eventually activates mito-
gen-activated protein kinases (MAPKs), including p38, JNK,
and extracellular signal-regulated kinase (ERK). MAPK acti-
vation leads to cytokine release (2).
However, the interaction between oral V. parvula LPS and
TLRs has not been directly studied yet. The aim of this study
was to investigate the potential role of TLR2 and TLR4 for the
recognition of Veillonella parvula LPS in both human periph-
eral blood mononuclear cells (PBMC) and in TLR2 and TLR4
knockout (KO) mouse macrophages, as well as the intracellu-
lar kinase signaling pathways induced after challenge of mono-
cytes with Veillonella parvula LPS.
MATERIALS AND METHODS
Veillonella parvula culture and LPS purification. V. parvula ATCC 10790
(American Type Culture Collection, Rockville, MD) was grown anaerobically in
modified lactate broth at 37°C. After V. parvula reached the early stationary
phase (about 40 h of incubation), bacterial cells were harvested by centrifugation
* Corresponding author. Mailing address: Department of Medicine,
Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500
HB Nijmegen, The Netherlands. Phone: 31-24-3614652. Fax: 31-24-
3541734. E-mail: l.joosten@aig.umcn.nl.
 Published ahead of print on 14 October 2009.
1804
 o
n
 February 12, 2013 by Universiteitsbibliotheek
http://cvi.asm
.org/
D
ow
nloaded from
 
and washed twice in 50 mM potassium phosphate buffer (pH 7.0) containing 20
mM 2-mercaptoethanol (PPB). Cells were extracted twice with phenol-water
(38). Briefly the aqueous layers were combined and dialyzed against 20 liters of
distilled water at 4°C. The crude LPS was lyophilized and then dissolved in
distilled water and centrifuged once at 80,000  g for 7 h at 4°C. The pellet was
suspended in distilled water and recentrifuged twice at 105,000 g for 3 h at 4°C.
The LPS was dissolved in PPB with RNase (Sigma, Chemical Co., St. Louis, MO)
and DNase (Sigma) at 20 g/ml each. After 2 h of incubation at 37°C, the
solution was centrifuged at 105,000  g for 3 h at 4°C. The pellet was washed in
distilled water and centrifuged twice at 105,000  g at 4°C. The final pellet was
dissolved in distilled water, lyophilized, and stored at 20°C as once-purified
LPS. Double-step-purified LPS (repurified LPS) was obtained following the
method described by Hirschfeld et al. (17).
Isolation of peripheral blood mononuclear cells and stimulation of cytokine
production. Isolation of PBMC was performed as described elsewhere (1), with
minor modifications. All volunteers signed an inform consent form, according to
the institutional guidelines and procedures. A total of 5  105 PBMC in a 100-l
volume were added to round-bottom 96-well plates (Greiner) and incubated with
either 100 l of culture medium or the various stimuli: highly purified Veillonella
LPS (1 to 100 ng/ml), highly purified E. coli LPS (1 ng/ml; Sigma), or Pam3Cys
(10 g/ml; EMC Microcollections). In some experimental sets, cells were pre-
treated with or without double-extracted Bartonella quintana LPS (1 g/ml), a
TLR4 antagonist (31), 30 min before treatment with V. parvula LPS (100 ng/ml).
Specific signal transduction inhibitors of p38 MAPK (SB202190; 25 m),
ERK1/2 (U0126; 25 m), JNK1/2/3 kinase (SP600125; 25 m) (all inhibitors
purchased from Superarray Bioscience Corporation, Bethesda, MD) were added
to the cultures for 45 min prior to addition of Veillonella LPS. All unstimulated
and control samples received an equal amount of inhibitor solvent, dimethyl
sulfoxide (0.1% [vol/vol]). After 24 h of culture, the supernatants were collected,
centrifuged at 1,200 rpm, and stored at 80°C until assayed.
Isolation of peritoneal macrophages and stimulation of cytokine production.
For isolation of mouse peritoneal macrophages and spleen cells, groups of five
TLR2/ and TLR4/ mice (kindly provided by S. Akira, Osaka, Japan) and
their control littermates were sacrificed, and resident peritoneal macrophages
were harvested by injecting 4 ml of sterile phosphate-buffered saline containing
0.38% sodium citrate. After washing, the cells were resuspended in RPMI 1640
medium containing 1 mM pyruvate, 2 mM L-glutamine, 100 g/ml gentamicin,
and 2% fresh mouse plasma (culture medium). Cells were cultured in 96-well
microtiter plates (Greiner, Alphen, The Netherlands) at 105 cells per well, in a
final volume of 200 l. The cells were stimulated with either control medium or
highly purified Veillonella LPS (1 g/ml), highly purified E. coli LPS (1 ng/ml), or
Pam3Cys (10 ng/ml). After 24 h of incubation at 37°C, the plates were centrifuged
(500  g, 10 min), and the supernatant and cell lysate (three freeze-thaw cycles)
were collected and stored at 80°C until cytokine assays were performed.
Cytokine determinations. Human tumor necrosis factor alpha (TNF-), inter-
leukin-1 (IL-1), IL-6, and IL-10 were measured by using either specific or
commercial enzyme-linked immunosorbent assay (ELISA) kits (from R&D Sys-
tems, Abingdon, United Kingdom, and the Pelikine Compact from Sanquin,
Amsterdam, The Netherlands). Sensitivities of both ELISAs were below 5 pg/ml
(13). Murine IL-1 and TNF- were measured with a radioimmunoassay, and
murine IL-6 and IL-10 were determined using ELISA kits (R&D Systems,
Abingdon, United Kingdom).
Western blot analysis of Veillonella LPS signal transduction. After the isola-
tion of human PBMC, aliquots of the cells were placed in 3-cm sterile tissue
cultures plates in 1 ml of RPMI 1640 medium complemented with RPMI 1640
containing 10% fetal bovine serum, 10 mM L-glutamine, 100 U/ml penicillin, and
100 U/ml streptomycin (all obtained from Invitrogen, Carlsbad, CA). The cells
were immediately pretreated with or without the TLR4 antagonist B. quintana
LPS (1 g/ml) (31) added 30 min before treatment with V. parvula LPS (100
ng/ml).
At different time points the cells were collected and the proteins were ex-
tracted using a lysis buffer containing 50 mM HEPES (pH 7.4), 150 mM NaCl,
10 mM EDTA (pH 8), 10 mM Na4P2O7, 0.5% NP-40, 10% glycerol, 0.5 mM
dithiothreitol, 10 mM NaVO3, 100 mM NaF, 100 g/ml leupeptin, 0.5 mM
phenylmethylsulfonyl fluoride. After incubation for 30 min on ice, lysates were
centrifuged at 10,000  g for 10 min at 4°C. A 30-g portion of cell extract was
separated on a 10% sodium dodecyl sulfate-polyacrylamide gel and transferred
to a nitrocellulose membrane. Blots were incubated with anti-p38, anti-
phospho-p38, anti-ERK, anti-phospho-ERK, anti-JNK, or anti-phospho-JNK
(1:1,000; Cell Signaling), or anti-actin (1:200; Santa Cruz) antibodies and
then with anti-rabbit or anti-mouse horseradish peroxidase-coupled second-
ary antibody (Amersham, Buckinghamshire, United Kingdom). Immune com-
plexes were identified by using an enhanced chemiluminescence system (Am-
ersham, Buckinghamshire, United Kingdom).
Statistical analysis. The data are expressed as mean  standard errors of the
means unless indicated otherwise. Differences between experimental groups
were tested using the Mann-Whitney U-test, performed using GraphPad Prism
4.0 software. P values of 0.05 or less were considered significant.
RESULTS
V. parvula LPS is a weak stimulator of cytokine production
in human PBMC. Following stimulation with increasing
amounts of V. parvula LPS (1 to 100 ng/ml), human PBMC
released TNF- and IL-6 in a dose-related fashion. The high-
est concentration of V. parvula LPS used (100 ng/ml) released
an amount of the above cytokines that was comparable to that
produced by 1 ng/ml of the reference E. coli LPS (Fig. 1A and B).
A TLR4 antagonist blocks V. parvula LPS-induced cytokine
production. When human PBMC were pretreated with a TLR4
antagonist (B. quintana LPS at 1 g/ml), the release of TNF-
and IL-6 following stimulation with V. parvula LPS (1 to 100
FIG. 1. (A) TNF- production after exposure to Veillonella LPS.
Human PBMC were stimulated with a dose of purified Veillonella LPS
for 24 h. E. coli LPS served as a positive control. Data represent the
means  standard deviations for cytokine production by at least four
healthy volunteers. (B) IL-6 production. Cytokine levels were deter-
mined by an ELISA, and the detection limit was 20 pg/ml for both
cytokines.
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ng/ml), as well as with 1 ng/ml of the reference E. coli LPS, was
strongly inhibited (Fig. 2A and B).
TLR4 is the major receptor for V. parvula LPS-induced
cytokine production in mice. Resident peritoneal macrophages
were harvested from TLR2/ and TLR4/ mice and their
control littermates and stimulated in vitro with either control
medium or highly purified Veillonella LPS (1 g/ml), highly
purified E. coli LPS (1 ng/ml), or Pam3Cys (10 ng/ml). The
three stimuli used were able to produce a cytokine release
substantially higher than medium alone in control macrophage
cultures. Although Veillonella LPS caused a significant release
of cytokines in the macrophages from TLR2/ mice, it was
not able to induce a relevant release of cytokines among the
macrophages from TLR4/mice (Fig. 3A and B and 4A and B).
Veillonella-induced activation of p38 MAPK, which mediates
cytokine production. V. parvula LPS was able to activate the
human PBMC p38 MAPK after 60 minutes of incubation.
When B. quintana double-purified LPS was used to inhibit
TLR4 on PBMC, activation of p38 MAPK was hardly inhibited
after 60 minutes (Fig. 5A).
The activation of JNK and ERK1/2 after the V. parvula LPS
stimulus was very inconsistently observed regardless of the
time point considered (15, 30, and 60 min) (data not shown). In
line with these data, a p38 MAPK inhibitor strongly reduced
cytokine production induced by V. parvula LPS (Fig. 5B and
C). Similar results were observed with an inhibitor of JNK
kinase, while inhibition of ERK had a more modest effect (Fig.
5B and C).
DISCUSSION
In the present paper we demonstrate that V. parvula LPS is
recognized by TLR4 in both humans and mice and that the
activation of MAP kinases plays an important role in V. parvula
LPS-stimulated human PBMC signaling.
FIG. 2. Inhibition of Veillonella LPS-induced TNF- (A) and IL-6
(B) production by a TLR4 antagonist. PBMC were pretreated with
Bartonella quintana LPS for 1 h and then either Veillonella LPS or E.
coli LPS was added. Data represent the means  standard deviations
for cytokine production of at least four healthy volunteers. Note the
complete suppression of cytokine production after TLR4 blockade. *,
P  0.01 (Wilcoxon rank test).
FIG. 3. TLR2 is not activated by Veillonella LPS. Peritoneal mac-
rophages from wild-type and TLR2 gene-deficient mice were stimu-
lated with Veillonella LPS for 24 h. As a control, cells were stimulated
with Pam3Cys (a potent TLR2 ligand). (A) Murine TNF- and IL-10
production induced by Veillonella LPS. (B) Murine IL-1 and IL-6
levels. Note that Pam3Cys-induced cytokine production was abrogated
in TLR2 knockout (TLR2ko) cells. Data represent the means  stan-
dard deviations for cytokine production by at least five mice. *, P 
0.01 (Wilcoxon rank test).
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Previous studies on the in vitro and in vivo activities of the
LPS from Veillonella parvula demonstrated that such an endo-
toxin has biological effects comparable to enterobacterial LPS
(10, 29). Earlier studies reported on fibroblast collagenase-
inducing PBMC cytokines stimulated by Veillonella spp. LPS;
however, such cytokines were not directly evaluated (16). For-
malin-killed V. parvula has been demonstrated to induce the
release of IL-1 in human blood monocytes at levels compa-
rable to those released by Porphryomonas gingivalis, Bacte-
roides forsythus, and Prevotella intermedia (27). More recent
investigations showed that the concentrations of TNF-, IL-6,
and IL-10 released from umbilical cord and adult mononuclear
cells following in vitro challenge with UV-killed V. parvula
were comparable or even higher than cytokine concentrations
evaluated in Pseudomonas aeruginosa- and E. coli-stimulated
cord and adult cells (19).
The lower cytokine production of PBMC induced by Veil-
FIG. 5. Veillonella LPS activates p38 MAPK. (A) Effects of TLR4
inhibition by B. quintana LPS on Veillonella LPS-stimulated p38 acti-
vation in human PBMC. Protein extracts (30 g) were separated by
10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
analyzed by Western blotting using specific anti-p38 and anti-phopsho-
p38 antibodies. The intensity of phospho-p38-specific bands was mea-
sured by densitometry and is reported as arbitrary units (a.u.) of
phosho-p38 expression after normalization with p38 levels. The
means  standard errors of the means of three independent experi-
ments are shown. (B and C) Effects of pharmacological inhibition of
p38 MAPK-, JNK-, and ERK-mediated pathways during Veillonella
LPS stimulation of PBMC; the graphs show IL-1 and IL-6 production
after inhibition of p38 MAPK, JNK, and ERK (B) or TNF- and IL-19
production (C). Data represent the means  standard deviations for
cytokine production of at least four healthy volunteers. Note the strong
suppression of cytokine production after inhibition of p38 MAPK and
JNK. *, P  0.01 (Wilcoxon rank test).
FIG. 4. Veillonella LPS-induced cytokine production is TLR4 de-
pendent. Peritoneal macrophages from wild-type and TLR4 gene-
deficient mice were stimulated with Veillonella LPS for 24 h. As a
control, cells were stimulated with E. coli LPS (a potent TLR4 ligand).
(A) Murine TNF- and IL-10 production induced by Veillonella LPS.
(B) Murine IL-1 and IL-6. Note that both Veillonella LPS and E. coli
LPS induction of cytokine production was abrogated in TLR4 knock-
out (ko) cells. Data represent the means  standard deviations for
cytokine production by at least five mice. *, P  0.01 (Wilcoxon rank
test).
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lonella LPS (approximately 20 to 30% of that induced by E. coli
LPS) is mirrored in the type of pathology induced by these
microorganisms. On the one hand, gram-negative sepsis with
enterobacteriaceae induces a superacute inflammatory reac-
tion, followed sometimes by organ failure and even death. On
the other hand, Veillonella is present in the mouth flora and is
an important pathogen of periodontal disease, a chronic in-
flammatory condition. Thus, the low cytokine production by
Veillonella is certainly important in inducing the low-grade
inflammation in periodontitis.
To the best of our knowledge, very few papers have reported
on the role of TLRs for the pathogenesis of Veillonella infec-
tion. In one study treatment of dendritic cells with an anti-
TLR4 antibody decreased cytokine production induced by
UV-treated V. parvula (20), but the nature of the Veillonella
ligand recognized by TLR4 was not identified.
Similarly, TLR2- and TLR4-transfected human embryonic
kidney cells responded to sonicated Veillonella bacteria stimu-
lation (21). In both these studies, Veillonella seemed to stim-
ulate both TLR4 and TLR2. However, the bacterial product
responsible for the TLR engagement was not addressed, and
the models used were only from murine species. In the present
study, we demonstrate that V. parvula LPS is recognized by
TLR4 in both human and murine cells, and we show the
MAPK role in Veillonella LPS-stimulated human PBMC sig-
naling.
V. parvula has been implicated in both dental/periodontal
diseases (3, 18) and joint disorders (26). Periodontal disease
and rheumatoid arthritis have remarkably similar inflamma-
tory mediator profiles (22). Within periodontal lesions, acti-
vated monocytes, macrophages, and fibroblasts produce cyto-
kines, such as TNF-, IL-1, and IL-6, which have been found
to be significantly elevated in diseased periodontal sites com-
pared with healthy or inactive sites (11). These cytokines or-
chestrate the cascade of destructive events that occur in the
periodontal tissues and trigger the production of an array of
inflammatory enzymes and mediators, resulting in irreversible
hard and soft tissue damage (15). By exploiting an in vitro
model of periodontal diseases, it has been found that upregu-
lation of IL-6 by lipopolysaccharide treatment is TLR4 depen-
dent. This pattern of gene expression indicates that pathogens
may trigger TLR4 signaling and cause periodontitis (35).
Therefore, our present findings may have sound clinical im-
pact. Moreover, due to the similarity of pathogenesis between
periodontitis and rheumatoid arthritis, antagonists of TLR4, as
well as p38 inhibitors, have the potential to ameliorate pro-
gression of periodontal disease (23), rheumatic pathologies,
and other chronic inflammatory/degenerative disorders. The
TLR4 antagonist B. quintana LPS (31) has been demonstrated
to dramatically improve the evolution of experimental arthritis
in the mouse (1). Further studies are warranted in order to
exploit the modulation of TLR4 and p38 MAPK in the therapy
of chronic inflammatory/degenerative diseases.
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